OPDIVO
As listed in the register: OPDIVO 600 MG SOLUCION INYECTABLE
600 mg · solución inyectable
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Nivolumab
- Made by
- Bristol-Myers Squibb Pharma Eeig
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (OPDIVO). It describes the substance, not this exact product.
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production.
Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-12
Safety of the active substance
From the US prescribing label for the same active substance (OPDIVO). It describes the substance, not this exact product.
Most common adverse reactions (incidence ≥20%) in patients were:.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Bristol-Myers Squibb Pharma Eeig |
|---|---|
| Active substance | Nivolumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 600 mg |
| Form | solución inyectable |
| Classification | L01FF01 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | No — authorised but not currently marketed, according to the register |
| Driving | The regulator flags that this medicine can affect the ability to drive. |
| Name in the register | OPDIVO 600 MG SOLUCION INYECTABLE |
| Nº Registro | 1151014005 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
10 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- concentrado para solución para perfusión8 products
- solución inyectable2 products
600 mg2
600 mg · 2 companies
- Bristol-Myers Squibb Pharma Eeig · this page
- Bristol-Myers Squibb Pharma Eeig
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.